CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

Cited by (383)

Items 301–383 of 383

1. Abemacilib‐Related Radiation Recall Dermatitis Post Breast Reconstruction: A Case Report and Literature Review
   Zhaobo Jia, Lijin Gao, Xiaochuan Tang, Xinzhong Chang · 2026 · Thoracic Cancer
2. Genome-wide CRISPR/Cas9 screen identified MCL1 as a senolytic target for clearing palbociclib-induced senescent and PD-L1-positive cells in colorectal cancer
   Hao Wang, Tianqi Shen, Suisui Yang, Xiaohui Zhou, Pingping Cao, H Yu, Kexin He, Min Fu, H Yu, Xiaorong Liu et al. · 2026 · Cancer Letters
3. CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan
   Joshua Blume, Luisa Claus, Tamara Isermann, Antje Dickmanns, Lena‐Christin Conradi, Ramona Schulz‐Heddergott, Matthias Dobbelstein · 2023 · Cell Cycle
4. Involvement of the tumour necrosis factor receptor system in glioblastoma cell death induced by palbociclib-heptamethine cyanine dye conjugate
   Elizabeth Alexandra Cooper, Caitlin R. M. Oyagawa, Rebecca H. Johnson, Peter J. Choi, Jena Macapagal Foliaki, Jason A. Correia, Patrick M. Schweder, Peter A. Heppner, Edward T Mee, Clinton P. Turner et al. · 2024 · Cell Communication and Signaling
5. Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study
   Melissa Mahoney, Frankie Ann Holmes, Benjamin Cho · 2020 · Current Problems in Cancer Case Reports
6. Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study
   Fabrizio Nelli, Agnese Fabbri, Andrea Botticelli, Diana Giannarelli, Eleonora Marrucci, Cristina Fiore, Antonella Virtuoso, Julio Rodrigo Giròn Berrìos, Simone Scagnoli, Simona Pisegna et al. · 2023 · Frontiers in Oncology
7. Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim?
   Darya Javadrashid, Amir Baghbanzadeh, Nima Hemmat, Khalil Hajiasgharzadeh, Niloufar Sadat Nourbakhsh, Ziba Lotfi, Behzad Baradaran · 2021 · Immunology Letters
8. Inducing Cellular Senescence in Mouse Embryonic Fibroblasts (MEFs)
   Italo Lorandi, Han Li · 2024 · Methods in molecular biology
9. Integration of Next Generation Sequencing Data to Inform Survival Prediction of Patients with Spine Metastasis
   Alexandra Giantini-Larsen, Alexander D. Ramos, Axel S. Martin, Katherine S. Panageas, Caroline E. Kostrzewa, Zaki Abou-Mrad, Adam M. Schmitt, Jacqueline Bromberg, Anton Mikhailovich Safonov, Charles M. Rudin et al. · 2025 · Cancers
10. Combination of Cbl-b inhibitor NX-1607 and CDK4/6 inhibitor abemaciclib enhances anti-tumor immunity through PLCγ1/ERK-mediated T cell activation
    Shan Lu, Wen-Ting Zhu, Shan-Shan Song, Xubin Bao, Ting Yue Yu, Yongliang Zhang, Ze‐Hong Miao, Jin‐Xue He · 2025 · Cellular Signalling
11. CDK4/6 inhibitors display a class effect in inducing differentiation of neuroblastoma cells
    Kirsty M. Ferguson, Fiona M. Y. Abou Grealy, Anna Philpott · 2025 · Wellcome Open Research
12. Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
    Evan Rosenbaum P. E, Rodrigo Gularte‐Mérida, Evan Seffar, Jasme Lee, Matthew J. Adamow, Martina Bradić, Mark Andrew Dickson, Viswatej Avutu, Lauren Baker Banks, Jason Earl Chan et al. · 2025 · Cancer Research Communications
13. First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study
    Shoko Yao, Shigeru Imoto, Ai Tsuchiya, Hirotsugu Isaka, Hirohito Seki, Sota Asaga, Shigehiro Yokoi, Kenji Koneri, Hiroyuki Maeda, Takanori Goi · 2026 · Medicina
14. Reframing RB Tumor Suppressor Dysfunction as a Therapeutic Vulnerability in Cancer
    Rada Malko, Harlan E. Shannon, Erika A. Dobrota, Keiko E. Kreklau, Lauren K. Stevens, Kyle W. Jackson, Mohammad Reza Saadatzadeh, Pankita H. Pandya, Karen E. Pollok · 2026 · Cancers
15. Ribociclib-loaded folic acid conjugated chitosan-polycaprolactone hybrid nanoparticles for the management of glioblastoma
    Naveen Rajana, Sravani Ravula, Mural Quadros, Meghana Mokashi, Md Asrarul Islam, Dhwani Mehta, Mayssam Alkyam, Neelesh Kumar Mehra, Jeanette C. Perron, Dr. Sunil Kumar et al. · 2026 · Biomaterials Advances
16. CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
    Luis E Chinea, Caroline Hauer, Khushboo Pal, Hannah L. Chang, Isaac S. Chan · 2026 · Targeted Oncology
17. Elucidating the Unknown Role of Cyclin Dependent Kinase 5 in Cardiac Pathophysiological Conditions
    Danielle Aina-Badejo · 2021
18. A single-arm phase 2 study of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma
    Carson A. Wills, Suyash Mohan, Ali Nabavizadeh, Thara Patel, Timothy Prior, Maikel Mansour, Emily McCoy, Shivani A. Shah, Natalie Angeloni, Meghan O’Neill et al. · 2025 · Neuro-Oncology Advances
19. Abemaciclib-associated kidney injuries: A retrospective analysis of the United States Food and Drug Administration adverse events reporting system
    Xiangchun Xu, Xuzheng Guo, Jinhui Chen, Yuhua Pan, Jing Li, Jing Chen, Weihua Lai, Lin Lü · 2025 · Journal of International Medical Research
20. Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study
    Lara Emily Davis, Limin Zhu, Emile J. Latour, Nathan P. McMahon, Go Nishikawa, Florence Choo, Kevin D. Nusser, Janét Pittsenbarger, Reid Burch, Byung S. Park et al. · 2025 · Clinical Cancer Research
21. Advances in Molecular and Immunohistochemical Detection of Prognostic and Therapeutic Markers in Breast Cancer
    Rodrigo Vismari de Oliveira · 2020 · IntechOpen eBooks
22. The retinoblastoma protein mediates metabolic reprogramming in lung cancer.
    Lindsey R. Conroy · 2020 · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville)
23. Multi-Omics Analysis of Fibroblasts from the Invasive Tumor Edge Reveals that Tumor-Stroma Crosstalk Induces O-glycosylation of the CDK4-pRB Axis
    Gina Bouchard, Fernando Jose Garcia-Marques, Loukia Georgiou Karacosta, Weiruo Zhang, Abel Bermudez, Nicholas McIlvain Riley, Lindsey Catherine Mehl, Jalen Anthony Benson, Joseph B. Shrager, Carolyn Ruth Bertozzi et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
24. Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Xiaojiang Tian, Lin Chen, Yonghong Chen, Yi He, Ni Zhang · 2024 · Research Square
25. The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2
    Adam D Longhurst, Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N. Ward, Ian Richard Jones, Vivek Narayan, Frances V Hundley, Arshia Zernab Hassan, Charles M. Boone et al. · 2024 · eLife
26. Birth and death of cellular senescence
    Boshi Wang · 2020 · University of Groningen research database (University of Groningen / Centre for Information Technology)
27. A Co-Delivery Strategy of Abemaciclib Combined with Vitamin E Succinate Based on Hyaluronic Acid Modified Calcium Phosphate to Enhance the Anti-Cancer Effect
    Yuanyuan Liu, Na Gan, Shuangshuang Zhang, Qiaomei Sun, Xin Wei, Xiuyun Ren, Xi Xiang, Hui Li · 2021 · Research Square
28. Cyclin-dependent kinase inhibitors in cancer: bioanalysis and pharmacokinetics
    Diana Alejandra Martínez Chávez · 2021 · Utrecht University Repository (Utrecht University)
29. Cyclin-Dependent Kinases as Therapeutic Targets
    Mary E. Law, Brian Keith Law · 2021 · Springer eBooks
30. Targeted Therapy
    Maurizio D’Incalci, Elena Monti, Lorena Incorvaia, Marta Castiglia, Antonio Dello Russo, Viviana Bazan · 2021 · UNIPA Springer series
31. Cyclin-dependent kinases as therapeutic targets
    Mary E. Law, Brian Keith Law · 2021 · Springer eBooks
32. The kinetics and fragmentation of cell-free DNA from cultured cancer cells are influenced by anticancer treatments
    Prisca Bustamante, Mohamed Abdouh, Thupten Tsering, Julia Valdemarin Burnier · 2022 · Research Square
33. Cell cycle
    Aarthi Nivasini Mahesh, Karanpreet Singh Bhatia, Shruti Bhatt · 2023 · Elsevier eBooks
34. Supplementary Data from Multiomics Analysis of Spatially Distinct Stromal Cells Reveals Tumor-Induced O-Glycosylation of the CDK4–pRB Axis in Fibroblasts at the Invasive Tumor Edge
    Gina Bouchard, Fernando Jose Garcia-Marques, Loukia Georgiou Karacosta, Weiruo Zhang, Abel Bermudez, Nicholas McIlvain Riley, Sushama Varma, Lindsey Catherine Mehl, Jalen Anthony Benson, Joseph B. Shrager et al. · 2023
35. Supplementary Tables and Figures from Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
    Kelsey W. Nassar, Jennifer D. Hintzsche, Stacey M. Bagby, Veronica L. Espinoza, Christophe J. Langouët-Astrié, Carol M. Amato, Tugs-Saikhan Chimed, Mayumi Fujita, William Robinson, Aik Choon Tan et al. · 2023
36. Data from Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
    Kelsey W. Nassar, Jennifer D. Hintzsche, Stacey M. Bagby, Veronica L. Espinoza, Christophe J. Langouët-Astrié, Carol M. Amato, Tugs-Saikhan Chimed, Mayumi Fujita, William Robinson, Aik Choon Tan et al. · 2023
37. Data from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
    Caroline E. Gleason, Mark Andrew Dickson, Mary E. Klein, Cristina R. Antonescu, Rodrigo Gularte‐Mérida, Marimar Benitez, Juliana I. Delgado, Raghu P. Kataru, Mark Wei Yi Tan, Martina Bradić et al. · 2024
38. Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review
    Nikolai A. Ognerubov · 2024 · Journal of Modern Oncology
39. The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2
    Adam D Longhurst, Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N. Ward, Ian R. Jones, Vivek Narayan, Frances V Hundley, Arshia Zernab Hassan, Charles M. Boone et al. · 2025 · eLife
40. Targeting Stat3 Potentiates Cdk4/6 Inhibitors Therapy in Hnscc
    Dong Lin, Haoyang Sun, Chao Liu, Mo Wang, Mengyu Sun, Jianwei Zheng, Xiaoxue Yu, Rong Shi, Bo Wang, Qianqian Zhou et al. · 2024 · SSRN Electronic Journal
41. The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2
    Adam D Longhurst, Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N. Ward, Ian R. Jones, Vivek Narayan, Frances V Hundley, Arshia Zernab Hassan, Charles M. Boone et al. · 2024 · eLife
42. CDK4/6 inhibitors display a class effect in inducing differentiation of neuroblastoma cells
    Kirsty M. Ferguson, Fiona M. Y. Abou Grealy, Anna Philpott · 2024 · Wellcome Open Research
43. Research Progress on CDK4/6 Inhibitors Combined with Endocrine Therapy for Advanced Breast Cancer
    Qingfeng Wu, Lishan Xu, Lu Gan · 2024 · Journal of Contemporary Medical Practice
44. WITHDRAWN: Letter Re: A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
    Xudong Zhu, Tong Zhu, Xi Gu · 2025 · Annals of Oncology · Retracted
45. Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world Study
    Yingbo Shao, Yaning He, Fangfang Guo, Zhifen Luo, Yang Yu, Chaojun Liu, Qi Chen, Fangyuan Zhu, Hui Liu · 2025 · Research Square
46. Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma
    Shikha Gupta, Prateek Khanna, Eddy Saad, Renée Maria Saliby, Shatha AbuHammad, Jiao Li, Bingchen Li, Prathyusha Konda, Usman Ali Ahmed, Ananthan Sadagopan et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
47. WXJ-114, A New CDK4/6 Inhibitor that Treats Breast Cancer by Blocking Cell Cycles
    Jing Ji, Jiaojiao Zhou, Xiao Hou, Luyao Zhang, Lingyi Zuo, Hanxue Li, Meiqi Zhang, Yuanyuan Liu, Xing Liu, Qilan Qian et al. · 2025 · Pharmaceutical Chemistry Journal
48. CDK4/6 inhibition induces a DNA damage-independent senescence-associated secretory phenotype driven by delayed activation of NF-κB
    Joanna Lan-Hing Yeung, Justin Rendleman, Lauren Anderson Westcott, Arnold Ou, Matthew Pressler, Nicole Pagane, Irene Duba, Ria Hosuru, Bat‐Ider Tumenbayar, Viviana I. Risca · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
49. Exploratory Analysis of Regulated Cell Death-Related Genes as Potential Prognostic Biomarkers in Endometrial Carcinoma
    Yan‐Tong Lin, Dongyan Cao · 2025 · Biomedicines
50. Nanotechnology for combating chemoresistance in peripheral cancers
    Cleona Elizabeth Mary DCruz, Abhishek Dhiman, Arka Karmakar, Rupesh Kalidas Shirodkar, Lalit Kumar · 2025 · Elsevier eBooks
51. The Inhibition of CDK4/6 regulates the activity of multidrug resistance pumps in glioblastoma
    Yusuf Yilmaz, Hacer Ağar, Kaan Furkan Hamarat, Gamze Tanrιöver, Gamze Güney Eskiler · 2025 · Cytotechnology
52. Additional file 10 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Min Hwan Kim, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Kim, Jee Ye, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
53. Additional file 1 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Min Hwan Kim, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Kim, Jee Ye, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
54. Additional file 4 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Min Hwan Kim, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Jee Ye Kim, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
55. Additional file 5 of Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality
    Benfatto, Salvatore, Özdemirhan Serçin, Francesca R. Dejure, Abdollahi, Amir, Zenke, Frank T., Balca R. Mardin · 2021 · Figshare
56. Additional file 3 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Min Hwan Kim, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Kim, Jee Ye, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
57. Additional file 6 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Kim, Min Hwan, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Kim, Jee Ye, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
58. Additional file 5 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Min Hwan Kim, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Kim, Jee Ye, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
59. Additional file 8 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Min Hwan Kim, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Kim, Jee Ye, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
60. Additional file 1 of Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wei Wang, Wenqian Lei, Fang, Ziru, Jiang, Ruiyuan, Wang, Xiaojia · 2024 · Figshare
61. Additional file 7 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Min Hwan Kim, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Kim, Jee Ye, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
62. Additional file 9 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Kim, Min Hwan, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Kim, Jee Ye, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
63. Additional file 2 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Kim, Min Hwan, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Kim, Jee Ye, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
64. Additional file 1 of Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
    Lauren Darrigues, Jean‐Yves Pierga, Bernard-Tessier, Alice, Ivan Bièche, Amanda Bortolini Silveira, Marc Michel, Delphine Loirat, Paul Henri Cottu, Luc Cabel, Coraline Dubot et al. · 2021 · Figshare
65. Additional file 11 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Kim, Chang Gon, Min Hwan Kim, Kim, Jee Hung, Kim, Seul-Gi, Gun Min Kim, Kim, Tae Yeong, Ryu, Won-Ji, Kim, Jee Ye, Park, Hyung Seok, Seho Park et al. · 2024 · Figshare
66. Identification par séquençage de l'exome de la dérégulation des voies de signalisation dans le myélome multiple et leurs conséquences fonctionnelles, notamment sur la voie p53
    Benoît Tessoulin · 2018 · theses.fr (ABES)
67. Plasticité cellulaire et initiation tumorale dans le modèle du cancer du sein
    Hadrien De Blander · 2020 · theses.fr (ABES)
68. CDK4 inhibition by luteolin enhances lenvatinib sensitivity in HCC via Wnt/β-catenin modulation
    Baohong Yuan, Ruotian Wang, Ruhong Li, Songlin Yang, Dong Zhan, Jing Tan · 2026 · Cancer Cell International
69. A novel recombinant peptide, rAnguillin, induces ferroptosis in nasopharyngeal carcinoma by promoting FOXM1 degradation and disrupting the FOXM1-PABPC1L-tryptophan metabolism axis
    Qianhui Yuan, Yan Zhao, Fuxin Zhou, Yuebin Zhang, Xinyue Jia, Jihong Yao, Mei Lv, Jihong Wang, Li Lv · 2026 · International Journal of Biological Macromolecules
70. “Carry-Over” Effect of CDK4/6 Inhibitors in Adjuvant Therapy for Hormone Receptor (HR)-Positive/HER2-Negative Early Breast Cancer: Clinical Evidence and Molecular Approach
    Guillermo Valencia, Zaida Morante, Yomali Ferreyra, Rosario Jacome, Patricia Rioja, Alexandra Saavedra, Silvia P. Neciosup, Tatiana Vidaurre, Henry Gómez · 2026 · Biomedicines
71. Adjuvant endocrine therapy in estrogen-low breast cancer in the era of CDKI: are we at another uncertain crossroads?
    Maria Rosaria Valerio, Giuseppa Scandurra, Martina Greco, Chiara Mesi, Vittorio Gebbia, Daniela Sambataro · 2026 · Frontiers in Oncology
72. Investigation of the effect of Abemaciclib on breast cancer spheroids in a three-dimensional (3D) environment
    Can Sürücüoğlu, Selen Öztürk, Aysun Kılıç Süloğlu · 2026 · Biotech Studies
73. CDK4/6 inhibition induces a senescence-associated secretory phenotype via delayed NF-κB activation
    Joanna Lan-Hing Yeung, Justin Rendleman, Lauren Anderson Westcott, Arnold Ou, Matthew Pressler, Nicole Pagane, Irene Duba, Ria Hosuru, Bat‐Ider Tumenbayar, Viviana I. Risca · 2026 · Life Science Alliance
74. Plasma 4β-Hydroxycholesterol Predicts Ribociclib CYP3A-Mediated Metabolism, but Not Plasma Exposure, in Patients with Primary Brain Cancer
    Charuka D. Wickramasinghe, Xun Bao, Yuanyuan Jiang, Jun Jiang, Yang Yue, Nader Sanai, Jing Li · 2026 · Cancers
75. Cytotoxic profile, molecular modeling, cell cycle arrest, and apoptosis induced by CDK4/6 inhibitors
    Ankita Kumari, Ravi Raj, Yogendra Padwad · 2026 · Elsevier eBooks
76. Cell-cycle control of chromatin creates a therapeutic window for epigenetic therapy in tumors
    Kourosh Hayatigolkhatmi, Riccardo Valzelli, Elena Ceccacci, Amir Hosseini, Oualid El Menna, Mauro Romanenghi, Isabella Pallavicini, Emanuel Soda, Ornella Ejlli, Emanuela Villa et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
77. Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21
    Shiyi Yu, Xue Qin Gong, Yawen Yang, Ying Duan, Siyu Zhang, Ying Wang, Zheng Wang, Caili Bi, Haibo Sun · 2026 · Science Advances
78. Next-generation CDK inhibitors in HR+/HER2– breast cancer
    Daria Seriak, Jun Yong Kim, Geoffrey Ira Shapiro, Antonio Giordano · 2026 · Journal of Clinical Investigation
79. BindingDB Entry 50006788: How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
    BindingDB · 2021 · UC San Diego
80. BindingDB Entry 50017151: Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
    BindingDB · 2023 · UC San Diego
81. BindingDB Entry 50013278: Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
    BindingDB · 2022 · UC San Diego
82. BindingDB Entry 50009433: Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
    BindingDB · 2021 · UC San Diego
83. BindingDB Entry 50017849: Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.
    BindingDB · 2023 · UC San Diego